Diagnostic and Prognostic Model of Pulmonary Fibrosis After COVID-19 Pneumonia and Mechanism Study

Kunming Medical University

Status: Not yet enrolling

Conditions: COVID-19; Pulmonary Fibrosis

Treatments: Diagnostic Test: observational study

Study type: Observational

Funder types: Other

Identifiers

NCT05719038

KunmingMC

Details and patient eligibility

About

The infection of COVID-19 has caused serious threat to the life and health of all mankind and increased huge economic burden. According to the current statistics, the incidence of pulmonary fibrosis after COVID-19 infection is about 27.7% -87%, 81% of severe patients and 37% of moderate patients have residual lung lesions, and 53% of patients still have residual lung abnormalities one year after infection, resulting in restrictive pulmonary dysfunction and affecting the health and life of patients. Therefore, it is very important to study the diagnostic and prognostic markers of pulmonary fibrosis after infection of COVID-19. At present, relevant studies have been carried out on imagomics and serum proteomics of pulmonary fibrosis after COVID-19 infection, and serum biomarkers and imagomics marker models for diagnosing pulmonary fibrosis after COVID-19 pneumonia have been developed. However, there are few studies combining imageomics and serum proteomics, and the mechanism of pulmonary fibrosis after COVID-19 has not been fully clarified. In this study, it is planned to recruit patients with moderate, severe and critical COVID-19 pneumonia infection, collect venous blood from subjects, and perform chest HRCT follow-up. Blood samples were screened by proteomics and verified by expanded samples to screen diagnostic and prognostic markers of pulmonary fibrosis after COVID-19 infection. At the same time, based on deep learning technology, a model was developed to predict the occurrence and prognosis of pulmonary fibrosis after infection of COVID-19 combined with clinical characteristics, serum markers and AI imagomics, so as to provide ideas for further elucidating the mechanism of occurrence and development of pulmonary fibrosis after infection of COVID-19.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. age 18-90 years
2. novel coronavirus nucleic acid or antigen confirmed novel coronavirus infection
3. Meet the diagnostic criteria for moderate/severe/severe coronavirus infection in China (Trial Tenth Edition)
4. Chest CT showed that the extent of lung lesions was greater than 50%

Exclusion criteria

1. pregnant and lactating women
2. previous severe lung disease, such as known chronic lung disease: chronic obstructive pulmonary disease, asthma, interstitial lung disease, etc.
3. severe organ dysfunction: severe liver, kidney and heart dysfunction
4. severe epidemic defects (including tumors/severe rheumatism/organs, bone marrow transplantation/HIV, etc.)
5. inappropriate enrollment judged by the investigator

Trial design

200 participants in 3 patient groups

Healthy control group

Treatment:

Diagnostic Test: observational study

Pulmonary fibrosis after COVID-19 Pneumonia

Treatment:

Diagnostic Test: observational study

No pulmonary fibrosis after COVID-19 Pneumonia

Treatment:

Diagnostic Test: observational study